Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations

CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus

(2015) M. R. Russell et al.   CANCER RESEARCH

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

(2015) Thomas F Eleveld et al.   NATURE GENETICS

Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma

(2015) Lindi Chen et al.   Oncotarget

Detection of tumorALKstatus in neuroblastoma patients using peripheral blood

(2015) Valérie Combaret et al.   Cancer Medicine

The Risk-Associated Long Noncoding RNA NBAT-1 Controls Neuroblastoma Progression by Regulating Cell Proliferation and Neuronal Differentiation

(2014) Gaurav Kumar Pandey et al.   CANCER CELL

ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma

(2014) Scott C. Bresler et al.   CANCER CELL

Common Genetic Variants in NEFL Influence Gene Expression and Neuroblastoma Risk

(2014) M. Capasso et al.   CANCER RESEARCH

Intragenic anaplastic lymphoma kinase (ALK) rearrangements: Translocations as a novel mechanism ofALKactivation in neuroblastoma tumors

(2014) Susanne Fransson et al.   GENES CHROMOSOMES & CANCER

Emergence of New ALK Mutations at Relapse of Neuroblastoma

(2014) Gudrun Schleiermacher et al.   JOURNAL OF CLINICAL ONCOLOGY

Liquid Biopsies: Genotyping Circulating Tumor DNA

(2014) Luis A. Diaz et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical features of ATRX or DAXX mutated neuroblastoma

(2014) Sho Kurihara et al.   JOURNAL OF PEDIATRIC SURGERY

Rare Variants in TP53 and Susceptibility to Neuroblastoma

(2014) Sharon J. Diskin et al.   JNCI-Journal of the National Cancer Institute

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

(2014) Adam S. Crystal et al.   SCIENCE

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

(2014) C. Bettegowda et al.   Science Translational Medicine

Weaver syndrome andEZH2mutations: Clarifying the clinical phenotype

(2013) Katrina Tatton-Brown et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

CDK4 inhibition restores G₁-S arrest inMYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage

(2013) Sina Gogolin et al.   CELL CYCLE

New Strategies in Neuroblastoma: Therapeutic Targeting of MYCN and ALK

(2013) G. Barone et al.   CLINICAL CANCER RESEARCH

Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

(2013) J. Rader et al.   CLINICAL CANCER RESEARCH

BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma

(2013) P. Bandopadhayay et al.   CLINICAL CANCER RESEARCH

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

(2013) Yael P Mossé et al.   LANCET ONCOLOGY

The genetic landscape of high-risk neuroblastoma

(2013) Trevor J Pugh et al.   NATURE GENETICS

Detection of MYCN amplification using blood plasma: noninvasive therapy evaluation and prediction of prognosis in neuroblastoma

(2013) Masato Kojima et al.   PEDIATRIC SURGERY INTERNATIONAL

Breakpoint Features of Genomic Rearrangements in Neuroblastoma with Unbalanced Translocations and Chromothripsis

(2013) Valentina Boeva et al.   PLoS One

BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models

(2013) Anastasia Wyce et al.   PLoS One

Massively Parallel Sequencing Reveals an Accumulation of De Novo Mutations and an Activating Mutation of LPAR1 in a Patient with Metastatic Neuroblastoma

(2013) Jun S. Wei et al.   PLoS One

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

(2013) Alexandre Puissant et al.   Cancer Discovery

Neuroblastoma and MYCN

(2013) M. Huang et al.   Cold Spring Harbor Perspectives in Medicine

Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project

(2012) G Schleiermacher et al.   BRITISH JOURNAL OF CANCER

Replication of Neuroblastoma SNP Association at the BARD1 Locus in African-Americans

(2012) V. Latorre et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

MAX and MYC: A Heritable Breakup

(2012) A. Cascon et al.   CANCER RESEARCH

Common Variation at BARD1 Results in the Expression of an Oncogenic Isoform That Influences Neuroblastoma Susceptibility and Oncogenicity

(2012) K. R. Bosse et al.   CANCER RESEARCH

Characterization of Rearrangements Involving the ALK Gene Reveals a Novel Truncated Form Associated with Tumor Aggressiveness in Neuroblastoma

(2012) A. Cazes et al.   CANCER RESEARCH

Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility

(2012) Mario Capasso et al.   CARCINOGENESIS

Association of Age at Diagnosis and Genetic Mutations in Patients With Neuroblastoma

(2012) Nai-Kong V. Cheung   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes

(2012) Jan J. Molenaar et al.   NATURE

Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma

(2012) Sharon J Diskin et al.   NATURE GENETICS

LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression

(2012) Jan J Molenaar et al.   NATURE GENETICS

Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma

(2012) Mark Sausen et al.   NATURE GENETICS

Targeting ALK in neuroblastoma—preclinical and clinical advancements

(2012) Erica L. Carpenter et al.   Nature Reviews Clinical Oncology

Two cases of localized neuroblastoma with multiple segmental chromosomal alterations and metastatic progression

(2012) Andres Morales La Madrid et al.   PEDIATRIC BLOOD & CANCER

Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes

(2011) Christian P. Kratz et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling Pathways

(2011) N. Shukla et al.   CLINICAL CANCER RESEARCH

Copy number defects of G1-Cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis

(2011) Jan J. Molenaar et al.   GENES CHROMOSOMES & CANCER

Germline gain-of-function mutations of ALK disrupt central nervous system development

(2011) Loïc de Pontual et al.   HUMAN MUTATION

Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3

(2011) T. Van Maerken et al.   MOLECULAR CANCER THERAPEUTICS

A germline variant in the TP53 polyadenylation signal confers cancer susceptibility

(2011) Simon N Stacey et al.   NATURE GENETICS

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63

(2011) L D Gamble et al.   ONCOGENE

Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA

(2011) Valérie Combaret et al.   PEDIATRIC BLOOD & CANCER

RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma

(2011) K. A. Cole et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Altered Telomeres in Tumors with ATRX and DAXX Mutations

(2011) C. M. Heaphy et al.   SCIENCE

Phenotype Restricted Genome-Wide Association Study Using a Gene-Centric Approach Identifies Three Low-Risk Neuroblastoma Susceptibility Loci

(2011) Lễ B. Nguyễn et al.   PLoS Genetics

Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy

(2010) T. Martinsson et al.   CANCER RESEARCH

NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease Outcome

(2010) Michael Hölzel et al.   CELL

High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma

(2010) J. Carr-Wilkinson et al.   CLINICAL CANCER RESEARCH

Accumulation of Segmental Alterations Determines Progression in Neuroblastoma

(2010) Gudrun Schleiermacher et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcomes for Children and Adolescents With Cancer: Challenges for the Twenty-First Century

(2010) Malcolm A. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrative genomics identifies LMO1 as a neuroblastoma oncogene

(2010) Kai Wang et al.   NATURE

Selective inhibition of BET bromodomains

(2010) Panagis Filippakopoulos et al.   NATURE

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma

(2010) David L. Baker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recent Advances in Neuroblastoma

(2010) John M. Maris   NEW ENGLAND JOURNAL OF MEDICINE

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force

(2009) K Beiske et al.   BRITISH JOURNAL OF CANCER

Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma

(2009) Isabelle Janoueix-Lerosey et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study

(2009) Katherine K. Matthay et al.   JOURNAL OF CLINICAL ONCOLOGY

Copy number variation at 1q21.1 associated with neuroblastoma

(2009) Sharon J. Diskin et al.   NATURE

Common variations in BARD1 influence susceptibility to high-risk neuroblastoma

(2009) Mario Capasso et al.   NATURE GENETICS

High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors; Four cases of homozygous deletions of the CDKN2A gene

(2008) Helena Caren et al.   BMC GENOMICS

Germline PTPN11 missense mutation in a case of Noonan syndrome associated with mediastinal and retroperitoneal neuroblastic tumors

(2008) Léon Mutesa et al.   CANCER GENETICS AND CYTOGENETICS

Cyclin D1 and CDK4 Activity Contribute to the Undifferentiated Phenotype in Neuroblastoma

(2008) J. J. Molenaar et al.   CANCER RESEARCH

The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report

(2008) Tom Monclair et al.   JOURNAL OF CLINICAL ONCOLOGY

The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

(2008) Susan L. Cohn et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of ALK as a major familial neuroblastoma predisposition gene

(2008) Yaël P. Mossé et al.   NATURE

Activating mutations in ALK provide a therapeutic target in neuroblastoma

(2008) Rani E. George et al.   NATURE

Oncogenic mutations of ALK kinase in neuroblastoma

(2008) Yuyan Chen et al.   NATURE

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

(2008) Isabelle Janoueix-Lerosey et al.   NATURE

Chromosome 6p22 Locus Associated with Clinically Aggressive Neuroblastoma

(2008) John M. Maris et al.   NEW ENGLAND JOURNAL OF MEDICINE